{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Epstein-Peterson ZD"],"funding":["NCI NIH HHS"],"pagination":["5654-5662"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12848353"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(21)"],"pubmed_abstract":["<h4>Abstract</h4>The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post-CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to"],"journal":["Blood advances"],"pubmed_title":["Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis."],"pmcid":["PMC12848353"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Rhodes J","Chong EA","Shouval R","Lionel AC","Drill E","Ip A","Munoz JL","Varon B","Karmali R","Merryman RW","Kamdar MK","Zelenetz AD","Frank MJ","Sawalha Y","Riedell PA","van Besien H","Jacobson CA","Navalekar R","Wang Y","Yamshon S","Palomba ML","Jain P","Beyar-Katz O","Sharma S","Maddocks KJ","Brooks TR","Sauter CS","Epstein-Peterson ZD","Matasar MJ","Shukla N","Salles G","Dela Cruz J","Ryan CE","Atallah-Yunes SA","Chong ER","Therwhanger D","McLoughlin D","Joseph A","Kumar A","Iqbal M"],"additional_accession":[]},"is_claimable":false,"name":"Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.","description":"<h4>Abstract</h4>The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post-CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-14T06:07:28.451Z","creation":"2026-06-14T03:16:44.283Z"},"accession":"S-EPMC12848353","cross_references":{"pubmed":["40763269"],"doi":["10.1182/bloodadvances.2025016315"]}}